A prospective, nationwide cohort study found no increased risk for IBD linked to type 2 diabetes treatment with glucagon-like peptide-1 (GLP-1)-based therapies.
Heidi Søgaard Christensen, PhD, of Aalborg University Hospital in Denmark, presented real-world data on the potential risk associated with glucagon-like peptide-1 (GLP-1)-based therapies. The study compared exposure to GLP-1 receptor agonists and DPP4-inhibitors with other glucose-lowering agents by using data from Danish patient, prescription, and civil registration registries between 2007 and 2018.
The cohort included 177,950 patients with a new prescription for glucose-lowering medications. The median follow-up time was 4.8 years; the median age of the adult patients at study inception was 63.
A total of 412 cases of incident IBD were observed. Overall, treatment with one GLP-1-based therapy did not show an increased risk for developing IBD, with a statistically non-significant hazard ratio HR of 0.96 (95% CI, 0.72–1.27) in comparison with other diabetes drugs. Distinguishing between GLP-1 receptor agonists and DPP4-inhibitors also did not show significantly different IBD risks: HRs, 1.30 (95% CI, 0.86-1.96) and 0.84 (95% CI, 0.59-1.19), respectively.
Dr. Christensen stated that overall, no evidence for a risk of IBD following the use of a GLP-1-based therapy was detected. However, she noted that “the influence of GLP-1 receptor agonists may need further investigation to completely rule out a negative association.”
Copyright ©2023 Medicom Medical Publishers
